Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF)
USD 56.04
(14.37%)
USD 56.04
(14.37%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.32 Billion EUR | -1.19% |
| 2022 | 1.34 Billion EUR | 76.41% |
| 2021 | 760.47 Million EUR | -2.28% |
| 2020 | 778.23 Million EUR | -16.97% |
| 2019 | 937.34 Million EUR | 46.31% |
| 2018 | 640.64 Million EUR | 4.6% |
| 2017 | 612.46 Million EUR | 108.57% |
| 2016 | 293.64 Million EUR | 3.9% |
| 2015 | 282.61 Million EUR | -1.25% |
| 2014 | 286.2 Million EUR | 45.44% |
| 2013 | 196.78 Million EUR | 52.42% |
| 2012 | 129.11 Million EUR | -6.11% |
| 2011 | 137.51 Million EUR | 42.11% |
| 2010 | 96.76 Million EUR | 20.97% |
| 2009 | 79.99 Million EUR | -1.74% |
| 2008 | 81.4 Million EUR | 5.38% |
| 2007 | 77.25 Million EUR | -7.7% |
| 2006 | 83.69 Million EUR | -23.95% |
| 2005 | 110.05 Million EUR | -14.25% |
| 2004 | 128.34 Million EUR | 71.35% |
| 2003 | 74.9 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 1.3 Billion EUR | 0.0% |
| 2024 Q2 | 1.32 Billion EUR | 0.0% |
| 2023 FY | 1.32 Billion EUR | -1.19% |
| 2023 Q1 | 1.26 Billion EUR | -5.78% |
| 2023 Q2 | 1.47 Billion EUR | 16.34% |
| 2023 Q3 | 1.37 Billion EUR | -6.33% |
| 2023 Q4 | 1.32 Billion EUR | -3.77% |
| 2022 Q3 | 1.4 Billion EUR | -3.17% |
| 2022 FY | 1.34 Billion EUR | 76.41% |
| 2022 Q4 | 1.34 Billion EUR | -4.46% |
| 2022 Q1 | 1.4 Billion EUR | 84.57% |
| 2022 Q2 | 1.45 Billion EUR | 3.32% |
| 2021 Q3 | 824.7 Million EUR | -7.92% |
| 2021 Q4 | 760.47 Million EUR | -7.79% |
| 2021 FY | 760.47 Million EUR | -2.28% |
| 2021 Q1 | 800.32 Million EUR | 2.84% |
| 2021 Q2 | 895.64 Million EUR | 11.91% |
| 2020 Q3 | 898.96 Million EUR | -7.48% |
| 2020 Q4 | 778.23 Million EUR | -13.43% |
| 2020 FY | 778.23 Million EUR | -16.97% |
| 2020 Q1 | 937.44 Million EUR | 0.01% |
| 2020 Q2 | 971.6 Million EUR | 3.64% |
| 2019 FY | 937.34 Million EUR | 46.31% |
| 2019 Q3 | 1 Billion EUR | 60.22% |
| 2019 Q2 | 627.66 Million EUR | -2.94% |
| 2019 Q1 | 646.67 Million EUR | 0.94% |
| 2019 Q4 | 937.34 Million EUR | -6.79% |
| 2018 FY | 640.64 Million EUR | 4.6% |
| 2018 Q3 | 568.91 Million EUR | -3.08% |
| 2018 Q4 | 640.64 Million EUR | 12.61% |
| 2018 Q2 | 586.98 Million EUR | -1.84% |
| 2018 Q1 | 598.01 Million EUR | -2.36% |
| 2017 Q2 | 385.69 Million EUR | 37.64% |
| 2017 FY | 612.46 Million EUR | 108.57% |
| 2017 Q4 | 612.46 Million EUR | 14.52% |
| 2017 Q3 | 534.82 Million EUR | 38.67% |
| 2017 Q1 | 280.21 Million EUR | -4.57% |
| 2016 FY | 293.64 Million EUR | 3.9% |
| 2016 Q4 | 293.64 Million EUR | 18.8% |
| 2016 Q3 | 247.18 Million EUR | -4.78% |
| 2016 Q2 | 259.57 Million EUR | -2.29% |
| 2016 Q1 | 265.64 Million EUR | -6.0% |
| 2015 Q2 | 286.77 Million EUR | -0.28% |
| 2015 Q4 | 282.61 Million EUR | 3.17% |
| 2015 Q3 | 273.93 Million EUR | -4.48% |
| 2015 Q1 | 287.56 Million EUR | 0.48% |
| 2015 FY | 282.61 Million EUR | -1.25% |
| 2014 Q1 | 220.42 Million EUR | 12.01% |
| 2014 FY | 286.2 Million EUR | 45.44% |
| 2014 Q4 | 286.2 Million EUR | 7.12% |
| 2014 Q3 | 267.18 Million EUR | 25.38% |
| 2014 Q2 | 213.1 Million EUR | -3.32% |
| 2013 Q4 | 196.78 Million EUR | -12.07% |
| 2013 Q2 | 177.05 Million EUR | 36.41% |
| 2013 Q1 | 129.79 Million EUR | 0.53% |
| 2013 FY | 196.78 Million EUR | 52.42% |
| 2013 Q3 | 223.8 Million EUR | 26.41% |
| 2012 Q1 | 137.3 Million EUR | -0.15% |
| 2012 Q2 | 135.52 Million EUR | -1.3% |
| 2012 Q3 | 135.2 Million EUR | -0.24% |
| 2012 FY | 129.11 Million EUR | -6.11% |
| 2012 Q4 | 129.11 Million EUR | -4.51% |
| 2011 Q3 | 143.58 Million EUR | 6.31% |
| 2011 Q4 | 137.51 Million EUR | -4.23% |
| 2011 Q1 | 139.11 Million EUR | 43.77% |
| 2011 Q2 | 135.06 Million EUR | -2.91% |
| 2011 FY | 137.51 Million EUR | 42.11% |
| 2010 Q1 | 83.26 Million EUR | 4.09% |
| 2010 FY | 96.76 Million EUR | 20.97% |
| 2010 Q2 | 87.57 Million EUR | 5.19% |
| 2010 Q3 | 84.25 Million EUR | -3.8% |
| 2010 Q4 | 96.76 Million EUR | 14.85% |
| 2009 Q4 | 79.99 Million EUR | 0.0% |
| 2009 FY | 79.99 Million EUR | -1.74% |
| 2008 FY | 81.4 Million EUR | 5.38% |
| 2007 FY | 77.25 Million EUR | -7.7% |
| 2006 FY | 83.69 Million EUR | -23.95% |
| 2005 FY | 110.05 Million EUR | -14.25% |
| 2004 FY | 128.34 Million EUR | 71.35% |
| 2003 FY | 74.9 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.33 Billion USD | 94.065% |
| Bristol-Myers Squibb Company PFD CONV 2 | 38.18 Billion USD | 96.528% |
| CSPC Pharmaceutical Group Limited | 107.05 Million USD | -1138.188% |
| Clarus Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Novartis AG | 20.03 Billion USD | 93.383% |
| PT Kalbe Farma Tbk. | 19.39 Million USD | -6735.737% |